⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BCTX News
Briacell Therapeutics Corp. Common Shares
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
globenewswire.com
BCTX
BCTXW
BCTXZ
BCTXL
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
globenewswire.com
BCTX
BCTXW
BCTXZ
BCTXL
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
globenewswire.com
BCTX
BCTXW
BCTXZ
BCTXL
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
globenewswire.com
BCTX
BCTXW
BCTXZ
BCTXL
BriaCell Therapeutics Announces Closing of US$30 million Public Offering
globenewswire.com
BCTX
BriaCell Therapeutics Announces Pricing of $30 million Public Offering
globenewswire.com
BCTX
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient
globenewswire.com
BCTX
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
prnewswire.com
ONCY
BCTX
GLSI
CTOR
KZIA
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine
globenewswire.com
BCTX
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
globenewswire.com
BCTX